{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:40:54Z","timestamp":1790401254736,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-021-00773-1","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T07:02:52Z","timestamp":1636527772000},"page":"583-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection"],"prefix":"10.1007","volume":"22","author":[{"given":"Basant","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6909-8021","authenticated-orcid":false,"given":"Adel Abdel","family":"Moneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Mabrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"issue":"2","key":"773_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.dld.2015.10.016","volume":"48","author":"E Vanni","year":"2016","unstructured":"Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48(2):105\u201311.","journal-title":"Dig Liver Dis"},{"key":"773_CR2","doi-asserted-by":"publisher","first-page":"6150861","DOI":"10.1155\/2018\/6150861","volume":"2018","author":"S Drazilova","year":"2018","unstructured":"Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the Era of DAA therapy. Can J Gastroenterol Hepatol. 2018;2018:6150861.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"773_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1586\/egh.11.43","volume":"5","author":"V Kaddai","year":"2011","unstructured":"Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Rev Gastroenterol Hepatol. 2011;5(4):503\u201316.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"773_CR4","doi-asserted-by":"crossref","unstructured":"Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138(3):932\u2013941.","DOI":"10.1053\/j.gastro.2009.11.050"},{"issue":"1","key":"773_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","volume":"147","author":"C Hezode","year":"2014","unstructured":"Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype1 infection and cirrhosis. Gastroenterology. 2014;147(1):132-42.e4.","journal-title":"Gastroenterology"},{"issue":"12","key":"773_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/jmv.24897","volume":"89","author":"S Abdel Alem","year":"2017","unstructured":"Abdel Alem S, Elsharkawy A, Fouad R, et al. Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience. J Med Virol. 2017;89(12):2181\u20137.","journal-title":"J Med Virol"},{"issue":"3","key":"773_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15403\/jgld.2014.1121.273.daa","volume":"27","author":"P Weidner","year":"2018","unstructured":"Weidner P, Boettche D, Zimmerer T, et al. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2018;27(3):281\u20139.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"773_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10238-019-00605-3","volume":"20","author":"A Abdel Moneim","year":"2020","unstructured":"Abdel Moneim A, Suleiman HA, Mahmoud B, et al. Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4. Clin Exp Med. 2020;20(2):231\u201340.","journal-title":"Clin Exp Med"},{"issue":"3","key":"773_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1368-5031.2006.00825.x","volume":"60","author":"E Wright","year":"2006","unstructured":"Wright E, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006;60(3):308\u201314.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"773_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nut.2014.04.019","volume":"31","author":"M Andrews","year":"2015","unstructured":"Andrews M, Soto N, Arredondo-Olgu\u00edn M. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity. Nutrition. 2015;31(1):51\u20137.","journal-title":"Nutrition"},{"issue":"5","key":"773_CR11","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","volume":"46","author":"P Cacoub","year":"2014","unstructured":"Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extra-hepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(5):S165\u201373.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"773_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H. The IL-23\/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218\u201322.","journal-title":"J Clin Invest"},{"issue":"7","key":"773_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/ijms17071070","volume":"17","author":"P Meng","year":"2016","unstructured":"Meng P, Zhao S, Niu X, et al. Involvement of the interleukin-23\/interleukin-17 axis in chronic hepatitis C virus infection and its treatment responses. Int J Mol Sci. 2016;17(7):1070.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"773_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","volume":"16","author":"S Pflanz","year":"2002","unstructured":"Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16(6):779\u201390.","journal-title":"Immunity"},{"issue":"6","key":"773_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1089\/jir.2009.0093","volume":"30","author":"AC Frank","year":"2010","unstructured":"Frank AC, Zhang X, Katsounas A, et al. Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res. 2010;30(6):427\u201331.","journal-title":"J Interferon Cytokine Res"},{"issue":"15","key":"773_CR16","doi-asserted-by":"publisher","first-page":"11899","DOI":"10.1074\/jbc.M111.308064","volume":"287","author":"L Liu","year":"2012","unstructured":"Liu L, Cao Z, Chen J, et al. Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling. J Biol Chem. 2012;287(15):11899\u2013910.","journal-title":"J Biol Chem"},{"issue":"1","key":"773_CR17","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142014. Diabetes Care. 2014;37(1):S14\u201380.","journal-title":"Diabetes Care"},{"issue":"4","key":"773_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12072-018-9868-8","volume":"12","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int. 2018;12(4):348\u201355.","journal-title":"Hepatol Int"},{"issue":"7","key":"773_CR19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jgh.14067","volume":"33","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33(7):1379\u201382.","journal-title":"J Gastroenterol Hepatol"},{"key":"773_CR20","doi-asserted-by":"crossref","unstructured":"Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018; 90:320e7.","DOI":"10.1002\/jmv.24954"},{"issue":"4","key":"773_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/jgh3.12324","volume":"4","author":"R Nevola","year":"2020","unstructured":"Nevola R, Rinaldi L, Zeni L, et al. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4(4):713\u201321.","journal-title":"JGH Open"},{"key":"773_CR22","doi-asserted-by":"crossref","unstructured":"Yuan M, Zhou J, Du L, Yan L, Tang H. Hepatitis C virus clearance with glucose improvement and factors affecting the glucose control in chronic hepatitis C patients. Sci Rep. 2020; 6;10(1):1976.","DOI":"10.1038\/s41598-020-58786-x"},{"issue":"6","key":"773_CR23","first-page":"775","volume":"26","author":"J Andres","year":"2020","unstructured":"Andres J, Barros M, Arutunian M, Zhao H. Treatment of hepatitis C virus and long-term effect on glycemic control. J Manag Care Spec Pharm. 2020;26(6):775\u201381.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"773_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","volume":"41","author":"AA Dawood","year":"2017","unstructured":"Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J. 2017;41(4):316\u201321.","journal-title":"Diabetes Metab J"},{"issue":"2","key":"773_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","volume":"134","author":"R Moucari","year":"2008","unstructured":"Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416\u201323.","journal-title":"Gastroenterology"},{"key":"773_CR26","doi-asserted-by":"crossref","unstructured":"Gualerzi A, Bellan M, Smirne C, et al. Improvement of insulin sensitivity in diabetic and non-diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One. 2018;13(12):e0209216.","DOI":"10.1371\/journal.pone.0209216"},{"issue":"10","key":"773_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1515\/CCLM.2009.280","volume":"47","author":"M Persico","year":"2009","unstructured":"Persico M, Russo R, Persico E, et al. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clin Chem Lab Med. 2009;47(10):1217\u201325.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"773_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1478-3231.2008.01952.x","volume":"29","author":"L Serfaty","year":"2009","unstructured":"Serfaty L, Capeau J, Hepatitis C. insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(2):13\u201325.","journal-title":"Liver Int"},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2014.04.026","volume":"61","author":"A Boltjes","year":"2014","unstructured":"Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61:660\u201371.","journal-title":"J Hepatol"},{"key":"773_CR30","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","volume":"25","author":"C Arnaud","year":"2005","unstructured":"Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6\u2013induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005;25:1231\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"773_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.ELX.0000427103.05494.6c","volume":"3","author":"TI El Serafi","year":"2013","unstructured":"El Serafi TI, Awad MM, Eldeen LAT, El Serafi AT, Husin M. Effect of interleukin-6 and insulin resistance on early virological response of Egyptian chronic hepatitis C patients to combined pegylated interferon plus Ribavirin therapy. Egy Liver J. 2013;3:21\u20137.","journal-title":"Egy Liver J"},{"key":"773_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.21608\/bmfj.2017.69151","volume":"34","author":"FMA El Salam","year":"2017","unstructured":"El Salam FMA, El Toukhy NE, Mohamed AA, Nekola HA. Serum interleukin-6 concentration and association with response to hepatitis C virus therapy for chronic hepatitis C patients. Benha Med J. 2017;34:59\u201365.","journal-title":"Benha Med J"},{"key":"773_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.humimm.2014.08.198","volume":"75","author":"AM Tarrag\u00f4","year":"2014","unstructured":"Tarrag\u00f4 AM, da Costa AG, Pimentel JPD, et al. Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-\u03b1 polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients. Hum Immunol. 2014;75:1075\u201383.","journal-title":"Hum Immunol"},{"issue":"2","key":"773_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/jcm9020563","volume":"9","author":"DG Ribaldone","year":"2020","unstructured":"Ribaldone DG, Sacco M, Saracco GM. The Effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm. J Clin Med. 2020;9(2):563.","journal-title":"J Clin Med"},{"issue":"3","key":"773_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","volume":"102","author":"T Kawaguchi","year":"2007","unstructured":"Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"43","key":"773_CR36","doi-asserted-by":"publisher","first-page":"12361","DOI":"10.3748\/wjg.v21.i43.12361","volume":"21","author":"F Parvaiz","year":"2015","unstructured":"Parvaiz F, Manzoor S, Iqbal J, et al. Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol. 2015;21(43):12361\u20139.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"773_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.immuni.2008.03.001","volume":"28","author":"MJ McGeachy","year":"2008","unstructured":"McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445\u201353.","journal-title":"Immunity"},{"issue":"11","key":"773_CR38","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1681\/ASN.V11112044","volume":"11","author":"AM Woltman","year":"2000","unstructured":"Woltman AM, De Haij S, Boonstra JG, et al. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol. 2000;11(11):2044\u201355.","journal-title":"J Am Soc Nephrol"},{"key":"773_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cytogfr.2003.10.003","volume":"15","author":"D Miljkovic","year":"2004","unstructured":"Miljkovic D, Trajkovic V. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 2004;15:21\u201332.","journal-title":"Cytokine Growth Factor Rev"},{"key":"773_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1708853","volume":"3","author":"P Chen","year":"2020","unstructured":"Chen P, Lin L, Xu X, et al. Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin. J Dermatolog Treat. 2020;3:1\u20137. https:\/\/doi.org\/10.1080\/09546634.2019.1708853.","journal-title":"J Dermatolog Treat"},{"issue":"28","key":"773_CR41","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3748\/wjg.v18.i28.3738","volume":"18","author":"MF Schaalan","year":"2012","unstructured":"Schaalan MF, Mohamed WA, Amin HH. Vitamin D deficiency: correlation to interleukin-17, interleukin-23 and PIIINP in hepatitis C virus genotype 4. World J Gastroenterol. 2012;18(28):3738\u201344.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"773_CR42","first-page":"84","volume":"21","author":"MA Jimenez-Sousa","year":"2010","unstructured":"Jimenez-Sousa MA, Almansa R, de la Fuente C, et al. Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw. 2010;21(2):84\u201391.","journal-title":"Eur Cytokine Netw"},{"key":"773_CR43","doi-asserted-by":"crossref","unstructured":"Povroznik JM, Robinson CM. IL-27 regulation of innate immunity and control of microbial growth.\u00a0Future Sci OA. 2020;6(7): FSO588.","DOI":"10.2144\/fsoa-2020-0032"},{"issue":"3","key":"773_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1365-2893.2003.00412.x","volume":"10","author":"TJ Tang","year":"2003","unstructured":"Tang TJ, Kwekkeboom J, Laman JD, et al. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat. 2003;10(3):159\u201367.","journal-title":"J Viral Hepat"},{"issue":"4","key":"773_CR45","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.7314\/APJCP.2016.17.4.2093","volume":"17","author":"MM Fawzy","year":"2016","unstructured":"Fawzy MM, Wahid A, Nazmy MH, et al. Association of interleukin-27 rs 153109 single nucleotide polymorphism with spontaneous resolution of hepatitis C virus\u2014genotype 4a infection in Egyptian Patients. Asian Pac J Cancer Prev. 2016;17(4):2093\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"773_CR46","first-page":"32","volume":"114","author":"G Vargas-Alarc\u00f3n","year":"2019","unstructured":"Vargas-Alarc\u00f3n G, P\u00e9rez-Hern\u00e1ndez N, Rodr\u00edguez-P\u00e9rez JM, et al. Interleukin 27 polymorphisms, their association with insulin resistance and their contribution to subclinical atherosclerosis. The GEA Mexican study Cytokine. 2019;114:32\u20137.","journal-title":"The GEA Mexican study Cytokine"},{"key":"773_CR47","doi-asserted-by":"publisher","first-page":"8879758","DOI":"10.1155\/2020\/8879758","volume":"2020","author":"MS Abdel-Tawab","year":"2020","unstructured":"Abdel-Tawab MS, Fouad HH, Omran DA, et al. Evaluation of serum and gene expression of galectin-4, interleukin-27, and complement-7 in hepatitis C virus-infected Egyptian patients. Biomed Res Int. 2020;2020:8879758.","journal-title":"Biomed Res Int"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00773-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T03:28:37Z","timestamp":1666582117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00773-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research (ethics)"}},{"value":"The protocol of the study was approved by the Ethics Committee of the treatment center. Additionally, all patients received written consent and were treated by a study protocol in accordance with the Egyptian National guidelines which was conducted in compliance with the Declaration Helsinki and Guidelines of Clinical Practice (Decision date: 14.2.2018).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the authors consented to participate in the drafting of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable<b>.<\/b>","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Plant reproducibility"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}